303 related articles for article (PubMed ID: 16700548)
1. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.
Asher G; Dym O; Tsvetkov P; Adler J; Shaul Y
Biochemistry; 2006 May; 45(20):6372-8. PubMed ID: 16700548
[TBL] [Abstract][Full Text] [Related]
2. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
Asher G; Lotem J; Tsvetkov P; Reiss V; Sachs L; Shaul Y
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15065-70. PubMed ID: 14634213
[TBL] [Abstract][Full Text] [Related]
3. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1.
Asher G; Bercovich Z; Tsvetkov P; Shaul Y; Kahana C
Mol Cell; 2005 Mar; 17(5):645-55. PubMed ID: 15749015
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL; Megarity CF; Timson DJ
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
[TBL] [Abstract][Full Text] [Related]
5. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).
Megarity CF; Abdel-Aal Bettley H; Caraher MC; Scott KA; Whitehead RC; Jowitt TA; Gutierrez A; Bryce RA; Nolan KA; Stratford IJ; Timson DJ
Chembiochem; 2019 Nov; 20(22):2841-2849. PubMed ID: 31165578
[TBL] [Abstract][Full Text] [Related]
6. Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase(1.).
Lienhart WD; Gudipati V; Uhl MK; Binter A; Pulido SA; Saf R; Zangger K; Gruber K; Macheroux P
FEBS J; 2014 Oct; 281(20):4691-4704. PubMed ID: 25143260
[TBL] [Abstract][Full Text] [Related]
7. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems.
Dehn DL; Siegel D; Swann E; Moody CJ; Ross D
Mol Pharmacol; 2003 Sep; 64(3):714-20. PubMed ID: 12920209
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells.
Nolan KA; Scott KA; Barnes J; Doncaster J; Whitehead RC; Stratford IJ
Biochem Pharmacol; 2010 Oct; 80(7):977-81. PubMed ID: 20599803
[TBL] [Abstract][Full Text] [Related]
9. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.
Winski SL; Faig M; Bianchet MA; Siegel D; Swann E; Fung K; Duncan MW; Moody CJ; Amzel LM; Ross D
Biochemistry; 2001 Dec; 40(50):15135-42. PubMed ID: 11735396
[TBL] [Abstract][Full Text] [Related]
10. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells.
Reigan P; Colucci MA; Siegel D; Chilloux A; Moody CJ; Ross D
Biochemistry; 2007 May; 46(20):5941-50. PubMed ID: 17455910
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin.
Tsvetkov P; Asher G; Reiss V; Shaul Y; Sachs L; Lotem J
Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5535-40. PubMed ID: 15809436
[TBL] [Abstract][Full Text] [Related]
12. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
[TBL] [Abstract][Full Text] [Related]
13. Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism.
Timson DJ
Curr Drug Targets; 2017; 18(5):500-510. PubMed ID: 26201483
[TBL] [Abstract][Full Text] [Related]
14. Characterization and partial purification of microsomal NAD(P)H:quinone oxidoreductases.
Jaiswal AK
Arch Biochem Biophys; 2000 Mar; 375(1):62-8. PubMed ID: 10683249
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1).
Nolan KA; Doncaster JR; Dunstan MS; Scott KA; Frenkel AD; Siegel D; Ross D; Barnes J; Levy C; Leys D; Whitehead RC; Stratford IJ; Bryce RA
J Med Chem; 2009 Nov; 52(22):7142-56. PubMed ID: 19877692
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of (±)-dunnione and its ortho-quinone analogues as substrates for NAD(P)H:quinone oxidoreductase 1 (NQO1).
Bian J; Xu L; Deng B; Qian X; Fan J; Yang X; Liu F; Xu X; Guo X; Li X; Sun H; You Q; Zhang X
Bioorg Med Chem Lett; 2015 Mar; 25(6):1244-8. PubMed ID: 25677663
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.
Scott KA; Barnes J; Whitehead RC; Stratford IJ; Nolan KA
Biochem Pharmacol; 2011 Feb; 81(3):355-63. PubMed ID: 20970406
[TBL] [Abstract][Full Text] [Related]
18. Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity.
Megarity CF; Timson DJ
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31431515
[TBL] [Abstract][Full Text] [Related]
19. Evidence for NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated quinone-dependent redox cycling via plasma membrane electron transport: A sensitive cellular assay for NQO1.
Tan AS; Berridge MV
Free Radic Biol Med; 2010 Feb; 48(3):421-9. PubMed ID: 19932748
[TBL] [Abstract][Full Text] [Related]
20. Affinity-based small fluorescent probe for NAD(P)H:quinone oxidoreductase 1 (NQO1). Design, synthesis and pharmacological evaluation.
Bian J; Li X; Xu L; Wang N; Qian X; You Q; Zhang X
Eur J Med Chem; 2017 Feb; 127():828-839. PubMed ID: 27829520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
